

# Journal Pre-proof



Patient Satisfaction and Clinical Outcomes of Reverse Shoulder Arthroplasty: A Minimum of 10 Years Follow-Up

Mihir M. Sheth, MD, Brett L. Heldt, BS, Jennifer H. Spell, Emily A. Vidal, BS, Mitzi S. Laughlin, PhD, Brent J. Morris, MD, Hussein A. Elkousy, MD, T. Bradley Edwards, MD

PII: S1058-2746(21)00728-X

DOI: <https://doi.org/10.1016/j.jse.2021.09.012>

Reference: YMSE 5759

To appear in: *Journal of Shoulder and Elbow Surgery*

Received Date: 29 June 2021

Revised Date: 7 September 2021

Accepted Date: 17 September 2021

Please cite this article as: Sheth MM, Heldt BL, Spell JH, Vidal EA, Laughlin MS, Morris BJ, Elkousy HA, Edwards TB, Patient Satisfaction and Clinical Outcomes of Reverse Shoulder Arthroplasty: A Minimum of 10 Years Follow-Up, *Journal of Shoulder and Elbow Surgery* (2021), doi: <https://doi.org/10.1016/j.jse.2021.09.012>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of Journal of Shoulder and Elbow Surgery Board of Trustees.

## Patient Satisfaction and Clinical Outcomes of Reverse Shoulder Arthroplasty: A Minimum of 10 Years Follow-Up

*Authors:* Mihir M. Sheth, MD<sup>1</sup>; Brett L. Heldt, BS<sup>2</sup>; Jennifer H. Spell<sup>3</sup>; Emily A. Vidal, BS<sup>4,5</sup>; Mitzi S. Laughlin, PhD<sup>4,5</sup>; Brent J. Morris, MD<sup>4,6</sup>; Hussein A. Elkousy, MD<sup>4,5,7</sup>; T. Bradley Edwards, MD<sup>4,5,7</sup>

1. Department of Orthopaedic Surgery, Baylor College of Medicine, 7200 Cambridge Street Suite 10A, Houston, TX 77030, USA
2. Baylor College of Medicine, 7200 Cambridge Street Suite 10A, Houston, TX 77030, USA
3. Rice University, 6100 Main St, Houston, TX 77005, USA
4. Fondren Orthopedic Research Institute (FORI), 7401 South Main Street, Houston, TX 77030, USA
5. Texas Education and Research Foundation for Shoulder and Elbow Surgery, Inc. (TERFSES), 7401 South Main Street, Houston, TX 77030, USA
6. Baptist Health Medical Group Orthopedics and Sports Medicine, Baptist Health Lexington, 1760 Nicholasville Rd Suite 101, Lexington, KY 40503, USA
7. Fondren Orthopedic Group, Texas Orthopedic Hospital, 7401 South Main Street, Houston, TX 77030, USA

*Running title:* 10-year outcomes of RSA

*Corresponding author:* Mitzi S. Laughlin, PhD,

Fondren Orthopedic Research Institute (FORI), 7401 South Main Street, Houston, TX 77030, USA

Mitzi.Laughlin@fondren.com

*Source of funding:* No direct funding was received for this study; however, Wright Medical, Inc. supports the shoulder arthroplasty registry utilized in this study and the Fondren Orthopedic Research Institute (FORI) supports part of the study team (EAV and MSL).

Dr. Morris received financial support (Tornier, Inc.) for the database that was used to collect results for the study and has received IP royalties/work as a consultant for Wright Medical Technology, Inc. Tornier Inc./Wright Medical was not involved in any aspect of the study. Dr. Elkousy has received publication royalties from Elsevier. The commercial entity was not involved in any aspect of this study. Dr. Edwards received financial support (Tornier, Inc.) for the database that was used to collect results for the study and

has received IP royalties/work as a consultant for Wright Medical Technology, Inc. He also works as a paid consultant, presenter, or speaker for DJ Orthopedics and Smith and Nephew and receives royalties from DJ Orthopedics. None of the commercial entities were involved in any aspect of the study. The other authors, their immediate families, and any research foundation with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.

The Texas Orthopedic Hospital's institutional review board approved this study (TOH145).

**Abstract**

*Background:* Reverse shoulder arthroplasty (RSA) has been shown to reliably improve pain and functional outcomes for multiple pathologies. Despite its increasing utilization in the United States since its introduction in 2004, few studies have investigated long-term outcomes of this procedure. This information is vital in many ways, including durability of functional outcomes, complication profiles and implant survivorship.

*Methods:* Our prospectively collected shoulder arthroplasty registry included 471 patients who had undergone RSA prior to December 31, 2010 by a single surgeon at a high-volume shoulder arthroplasty center. The study sample included 94 patients with a minimum of 10 years follow-up, and we evaluated the indications for RSA, complications, pain, Single Assessment Numeric Evaluation (SANE), and patient satisfaction on these patients at baseline, 2-5 years, and 10 or more years of follow-up. Prosthesis survivorship was determined by Kaplan-Meier survival analysis performed with revision for any reason as the end point for all 471 patients in the study period regardless of follow-up interval.

*Results:* The 94 patients with at least 10 years of follow-up were 63% female (60) and 37% male (34), with an average age of  $66 \pm 10$  years at time of RSA. There were 71 (75%) primary RSAs and 23 (25%) revision RSAs. Patient-reported outcome measures at 10-years or more included a current pain rating averaging  $2 \pm 3$  on a 0 to 10 scale and Single Assessment Numeric Evaluation (SANE) of  $73 \pm 28$ . There was no deterioration in function or pain from mid-term to long-term follow-up, as the SANE and pain score changed by less than the MCID or improved in 87 and 90% of patients, respectively. Overall, patients were satisfied with the RSA procedure with 52 (56%) very satisfied, 24 (26%) satisfied, 13 (14%) dissatisfied, and 4 (4%) very dissatisfied. For the subset of 68 patients that were contacted for follow-up, 64 (94%) would have the procedure again and 4 (6%) would not. Kaplan-Meier prosthesis survival rate for all 471 RSA patients was 88% (95% CI: 84-92%) at 5-years and 81% (95% CI: 74-86%) at 10-years.

26 *Conclusions:* This study presents the largest American cohort of Grammont design RSA at a minimum  
27 10-year follow-up. While RSA provided clinically significant and durable improvements in pain and  
28 function, the complication and revision rates were higher than prior reports. Despite this, the vast majority  
29 of patients were satisfied and would have the procedure again.

30

31 **Level of evidence:** Level IV; Case Series; Treatment Study

32 **Keywords:** reverse total shoulder arthroplasty; Clinical Outcomes; clinical decision; patient-reported  
33 outcome measures; patient satisfaction

34

35

36

37 Reverse shoulder arthroplasty was approved in the United States in 2004 for the treatment of cuff  
38 tear arthropathy (CTA). Since its introduction, RSA has been shown to reliably improve pain and  
39 functional outcomes for CTA and other shoulder pathologies.<sup>1,5,7,8,10,18</sup> Despite its increasing utilization,<sup>11</sup>  
40 few studies have investigated long-term clinical outcomes. To our knowledge, only two contemporary  
41 studies have published minimum 10-year results of RSA.<sup>1,5</sup> Long-term follow-up studies provide  
42 information vital to clinical decision making, including survivorship, complication profiles, and patient  
43 function.

44 The purpose of this study was to report patient-reported outcomes, satisfaction, complications,  
45 revisions, and prosthesis survivorship of RSA performed by a single, high-volume shoulder arthroplasty  
46 surgeon at a minimum of 10 years using a Grammont-design prosthesis.

47

## 48 **Methods**

### 49 *Inclusion criteria*

50 Patients were consented and enrolled in our prospective single-surgeon shoulder arthroplasty  
51 registry beginning in 2004. A retrospective review of the registry was performed to identify all patients  
52 who had undergone RSA for any diagnosis prior to December 31, 2010. A total of 472 patients were

53 identified in the registry and one patient was excluded because of a primary diagnosis of sarcoma  
54 necessitating resection and complex reconstruction with RSA.

55

#### 56 *Surgical technique and Postoperative Rehabilitation*

57 The Aequalis Legacy and Legacy Long reverse shoulder arthroplasty systems were utilized  
58 (Tornier, Wright Medical, Memphis, TN, USA). These systems consist of a Grammont-design prosthesis  
59 with a medialized center of rotation and a 155° neck-shaft angle. Our surgical techniques and  
60 postoperative rehabilitation protocols have been previously well described.<sup>6</sup>

61

#### 62 *Patient-reported outcome measures*

63 Patients undergoing shoulder arthroplasty at our institution are asked to follow-up at yearly  
64 intervals. Patient-reported outcome measures, including the Single Assessment Numeric Evaluation  
65 (SANE), the Visual Analog Scale (VAS), and subjective patient satisfaction, are completed  
66 preoperatively and at each yearly clinic visit. In our sample of 471 patients, only 25 had completed the  
67 10-year follow-up in the clinic. Prior to contacting patients, we searched national, state, and local  
68 mortality indexes and identified 225 patients as deceased, resulting in 221 patients needing follow-up.  
69 Contact information for the 221 patients needing follow-up was extracted from clinical and hospital  
70 medical records and each patient was called at their last known phone number. Since this follow-up was  
71 at least 10 years after RSA, many patients had moved or changed contact information since their last  
72 clinical visit. We used local and state databases to try and locate patients for follow-up when the contact  
73 information was incorrect. At least 3 attempts were made to contact each patient before they were  
74 considered lost to follow-up.

75 Upon successful contact with a patient, the patient was asked if they could return to the clinic. A  
76 standardized phone questionnaire was administered if the patient was unable to return to clinic. The  
77 standardized phone questionnaire consisted of a subset of 7 questions relating to shoulder pain and  
78 function following RSA (Table 1). Patients that returned to the clinic answered the subset of phone

79 questions within the standard registry questionnaires except question #6 as it was only administered to the  
80 phone group “If you had to go back and do the same surgery again, would you have the surgery?”.

81

## 82 *Statistical analysis*

83 For patients with 10 years of follow-up or more, preoperative patient characteristics such as age at  
84 surgery, gender, and indication for RSA were evaluated and reported as mean, standard deviation, and  
85 range or counts and percentages as appropriate. Patient-reported outcome measures were compared at  
86 preoperative, early to mid-term (2-5 years), and final follow-up (>10 years) time points with linear mixed  
87 models; this analysis was performed for individual patients rather than using batched means at each time  
88 point. Prosthesis survivorship was determined by Kaplan-Meier survival analysis performed with revision  
89 (defined as removal or replacement of metal components) for any reason as the end point for all patients  
90 in the study period regardless of follow-up interval. All revisions after the initial procedure were included  
91 in the survivorship analysis for the first model and a second model excluded revisions due to trauma (i.e.,  
92 fall or motor vehicle accident). Isolated polyethylene exchanges were not considered revisions. Patients  
93 with less than 10 years follow-up were censored according to their last clinic follow-up date; in other  
94 words, only the number of patients with documented implant survival to a date were included in the  
95 denominator of calculating survival. Analyses were completed with Stata release 15 (StataCorp LP,  
96 College Station, Texas) and statistical significance was defined as  $P < .05$ . Clinical significance was  
97 achieved when patient-reported outcome measures changed more than the published minimal clinically  
98 important difference (MCID).

99

## 100 **Results**

101 Ninety-four patients completed clinical or phone follow-up after RSA at an average of 11.4 years  
102 with a range of 10.0-15.7 years (Table 2). The study population was 63% female (59) and 37% male (34)  
103 with an average age of  $66.4 \pm 9.6$  years at time of RSA. RSA was the primary arthroplasty procedure for  
104 70 (75%) patients and a revision procedure for 23 (25%). The most common indication for primary RSA

105 was cuff tear arthropathy (77%) followed by proximal humerus fracture (13%) (Table 3). The 23 revision  
106 patients had undergone anatomic TSA (7), hemiarthroplasty or bipolar hemiarthroplasty (11), or RSA (5)  
107 previously. There were no significant differences between primary and revision cases for age, gender,  
108 body mass index (BMI), and years of follow-up (all  $P > .05$ ). However, a higher percentage of patients had  
109 primary RSA on the dominant shoulder, (66%) while only 35% of patients had revision RSA on the  
110 dominant shoulder ( $P = .009$ ).

#### 111 *Patient-reported outcome measures*

112 Patient-reported outcome measures significantly improved from preoperative, early to mid-term  
113 (2-5 years), and final follow-up (Figure 1). Pain, as measured by visual analog scale (VAS), decreased  
114 from  $5.8 \pm 3.0$  preoperatively, to  $1.3 \pm 2.1$  at 2-5 years ( $P < .001$ ) and  $2.0 \pm 2.7$  at final follow-up ( $P < .001$ ).  
115 The Single Assessment Numeric Evaluation (SANE) showed similar improvement with scores changing  
116 from  $22.5 \pm 24.5$  preoperatively, to  $63.9 \pm 32.9$  at 2-5 years follow-up ( $P < .001$ ) and  $73.3 \pm 28.2$  at final  
117 follow-up ( $P < .001$ ). When stratifying the sample by primary and revision cases, both patient groups were  
118 significantly improved at 2-5 years and final follow-up (all  $P < .001$ ). Revision patients did not improve as  
119 much as primary patients, but this difference was small and non-significant for both pain and SANE (all  
120  $P > .05$ ).

121 All patients exceeded the minimal clinically important difference (MCID) score of 29 for SANE<sup>9</sup>  
122 and 1.4 for pain<sup>17</sup> when evaluating preoperative to final follow-up scores. MCID changes in outcome  
123 measures between the 2-5 year and 10-year follow-up periods occurred in a minority of patients as 64%  
124 changed less than the MCID between follow-up time points. For SANE, 23% of patients improved at or  
125 above the MCID between follow-up time periods and 13% reported deteriorating results while 26% of  
126 patients reported more pain (VAS) and 10% less pain (VAS) at the 10-year follow-up.

127 Patient satisfaction overall was high. Fifty-two (56%) patients were very satisfied, 24 (26%)  
128 satisfied, 13 (14%) dissatisfied, and 4 (4%) very dissatisfied. There were nine patients (10%) who were  
129 either very satisfied or satisfied at 2-5 years follow-up, and then later became dissatisfied or very



130 dissatisfied at 10-year follow-up. Of these patients, two patients were revised after 10 years (PJI and  
131 periprosthetic fracture), six had increased pain and one was unsatisfied with motion.

132           In the subset of 68 patients that were contacted by phone for follow-up, 64 (94%) would have the  
133 procedure again and 4 (6%) would not. The most frequent complaint at final follow-up was a lack of  
134 motion of their shoulder after the procedure.

135

### 136 *Complications, Revisions and Prosthesis Survival*

137           In this sample of primary and revision RSA patients, there were 64 complications in 60 patients  
138 after at least 10-years of follow-up (complication rate of 64%), and 48 patients (51%) required either a  
139 reoperation or component revision. Figure 2 illustrates the most common complications by postoperative  
140 time period.

141           In the primary RSA group, 41 of 71 patients (58%) had postoperative complications; 4 patients  
142 had multiple complications. They were, in order of frequency, dislocation (11), PJI (11), periprosthetic  
143 fracture (7), acromial stress fracture/reaction (5), aseptic baseplate loosening (4), subjective instability  
144 (defined as patients who felt that their shoulder was “clicking” or “near dislocating,” and whose  
145 symptoms improved after a polyethylene exchange) (2), traumatic glenoid loosening (1), early superficial  
146 wound infection (1), hematoma (1), symptomatic intra-articular loose body (1), and axillary nerve palsy  
147 (resolved at 6 months) (1). The percentage of patients who experienced complications that occurred  
148 during the 0-6 month, 6 month to 2 year, 2-5 year, 5-10 year and after 10 year timepoints for primary  
149 RSA were 24%, 16%, 21%, 32%, and 8%, respectively.

150           There were 18 component revisions after primary RSA (25%). To treat PJI, 4 patients underwent  
151 two-stage revision and 6 patients underwent resection arthroplasty. Four periprosthetic fractures required  
152 open reduction and internal fixation (ORIF) and revision to a long stem prosthesis. Three cases of aseptic  
153 baseplate loosening underwent revision of the glenoid component with iliac crest autograft, and one  
154 patient refused further revision. The case of traumatic glenoid loosening required baseplate revision. In  
155 addition to revisions, there were 10 closed reductions and polyethylene/glenosphere exchanges after

156 dislocations, 2 polyethylene exchanges for subjective instability, 1 removal of an intra-articular loose  
157 body and 1 bearing exchange for the wound infection.

158 In the revision RSA group, 19 of 23 (83%) patients had postoperative complications. These  
159 included PJI (6), dislocations (5), dislocations followed by diagnosis of PJI (3), periprosthetic humerus  
160 fracture (2), aseptic baseplate loosening (2), and aseptic humeral loosening (1). Twelve (53%) patients in  
161 the revision RSA group required revision. Of the 9 patients with PJI, 6 underwent resection arthroplasty,  
162 1 underwent two-stage revision and 2 were planned to undergo 2-stage revision but later elected to live  
163 with a spacer. The two cases of aseptic baseplate loosening underwent baseplate revision with iliac crest  
164 autograft, and the one case of aseptic humeral loosening underwent revision with a proximal humerus  
165 replacement prosthesis. In addition, there were 7 reoperations: 5 polyethylene exchanges for dislocation  
166 and 2 ORIF with stem revision of periprosthetic humeral shaft fractures. The percentage of patients who  
167 experienced complications that occurred during the 0–6-month, 6 month to 2 year, 2-5 year, and 5-10 year  
168 periods after revision RSA were 47%, 32%, 11%, and 11%, respectively.

169 Among the 30 patients (32%) who required a revision or reoperation, 14 patients (47%) required  
170 another operation during our follow-up period. In the primary and revision RSA groups, multiple  
171 reoperations or revisions were required in 8 (11%) and 6 (26%) of patients, respectively.

172 A Kaplan-Meier survival curve was used to analyze prosthesis survival, defined as retention of  
173 the originally implanted metal components (Fig 3). All patients regardless of follow-up time were  
174 included in the survivorship analysis and were censored at their last clinic follow-up date. The overall 5-  
175 and 10-year prosthesis survival rate was 88% (95% CI: 84-92%) and 81% (95% CI: 74-86%),  
176 respectively. In addition, Kaplan-Meier survival curve analysis was performed separately for revision  
177 RSA and excluding revisions due to trauma (Fig 3). After excluding revisions due to trauma, the 5- and  
178 10-year prosthesis survival rate was 89% (95% CI: 84-93%) and 82% (95% CI: 75-87%), respectively.

179

180

181 **Discussion**

182 This study reported a minimum of 10-year follow-up results of 93 RSA (71 primary, 23 revision)  
183 for multiple indications performed by a single, high volume shoulder arthroplasty surgeon using the  
184 Tornier Aequalis Legacy and Legacy Long prostheses and Grammont style RSA. To our knowledge, this  
185 is the largest American cohort of RSA results at long term follow-up.

186 Functional outcomes and satisfaction after RSA at 10 year follow-up were favorable in this study,  
187 and almost all patients would have undergone the procedure again. These results are consistent with prior  
188 reports with a minimum of 8 or 10 year follow-up (Table 4).<sup>1,5,13</sup>

189 There were high complication and revision rates seen in both the primary and revision groups in  
190 our study. Many of the complications led to multiple operations after RSA, which is consistent with prior  
191 reports that complications of RSA can spiral into multiple revision procedures.<sup>4</sup> There are numerous  
192 factors to consider when interpreting these findings. First, only 94 of 471 RSAs performed during the  
193 study period met inclusion criteria (i.e., completed outcomes survey with at least 10-year follow-up),  
194 which may introduce a bias towards patients who required longer follow-up for complications. This is  
195 partially supported by the 81% survival rate by Kaplan-Meier analysis which included those patients in  
196 whom implant survival could be confirmed at a clinic visit but did not complete survey follow-up.  
197 Second, the indications for RSA were narrower during the study period, and, in our practice, included  
198 more salvage scenarios than present day; this is largely anecdotal but is somewhat reflected in that 63% of  
199 patients who had a complication after RSA underwent one or more prior shoulder surgeries. Moreover,  
200 the senior surgeon was earlier on the RSA learning curve than present. Third, some complications that  
201 were included may not directly judge RSA performance, such as traumatic complications remote from the  
202 time of RSA, early wound infection and a retained intra-articular loose body. However, even after  
203 excluding these events, the complication rate in the primary group was still 46% and in the revision group  
204 74%. Regardless of factors that may have contributed to the high complication rates, this finding warrants  
205 continued study into long-term RSA outcomes.

206 The complication profile at 10 year follow-up is similar to prior studies, with the most common  
207 postoperative complications being dislocations, PJI and acromial stress fractures.<sup>2,3</sup> While the rate of

208 dislocations (15% for primary cases) and acromial stress fractures (7% in primary cases) is consistent  
209 with previous reports,<sup>2,3</sup> the 14% rate of PJI for primary arthroplasty was high compared to prior database  
210 or institutional registry reports around 1%.<sup>14,15</sup> This disparity may in part be related to this study's bias  
211 towards identifying patients who followed up for longer periods of time, and that database studies may  
212 underestimate the true incidence of PJI.<sup>19</sup> One new finding in this study is the high number of  
213 periprosthetic fractures (10% overall). While these may be chance events that could happen in any elderly  
214 population, they are notable given that the majority of fractures required a revision procedure.

215         This study adds to our understanding of long-term mechanical failures. The rate of aseptic  
216 glenoid failures (6% overall and in primary cases only) was somewhat higher than previous reports. Cuff  
217 et al<sup>5</sup> reported no cases and Bacle et al<sup>1</sup> had 4 cases, all of which were either custom implants with  
218 acromial fixation or felt to be technical error. Revision to BIO-RSA using iliac crest autograft provided  
219 good function and pain relief for all the patients in our study, and none have required subsequent revisions  
220 since then. We were unfortunately unable to obtain 10-year radiographs to comment on scapular notching  
221 and whether this progressed to aseptic loosening. Prior studies have found the prevalence of high grade  
222 notching (stage 3 or 4) ranges from 17-62%,<sup>1,7,10,12,16</sup> increases over time,<sup>12,16</sup> and is associated with  
223 deteriorating clinical outcomes.<sup>7</sup> No long-term series to date has found progression to glenoid loosening.  
224 There was only one case of humeral loosening in this study, and it was in a revision RSA case with poor  
225 bone quality, which is consistent with previously reported rates of about 2%. A prior radiographic study  
226 by Melis et al found that 52% of patients had lucencies greater than 2 mm around the humeral component  
227 and 6% had stem subsidence at 9.6 year follow-up;<sup>12</sup> however, there were no revisions for humeral  
228 loosening during their study period.<sup>13</sup> Overall, despite high all cause revision rates, long-term studies  
229 demonstrate low rates of aseptic glenoid and humeral loosening, and the significance of radiographic  
230 findings remains unclear.

231         The lack of deterioration in function between mid- and long-term follow-up is in slight contrast to  
232 previous studies suggesting more durable functional results with lateralized compared to Grammont  
233 design RSA<sup>1,5</sup>. While the results of these studies are a commonly cited reason to favor lateralized designs,

234 both studies showed significant reductions in range of motion over time, and the loss of active forward  
235 elevation was slightly greater in the lateralized design study than Grammont. Our study using a  
236 Grammont design did not show functional deterioration over time and we are not able to comment on  
237 changes in active motion. In short, there is evidence to support durable functional outcomes with both  
238 lateralized and Grammont designs.

239         This study has multiple limitations. As mentioned, the retrospective design and long-term follow-  
240 up may have biased our data towards patients who experienced complications. In addition, there may  
241 have been changes in surgical techniques and postoperative management over the study period. More  
242 detailed functional scores would add to our understanding of the factors contributing to patients who were  
243 dissatisfied or reported a low SANE score. For example, Bacle et al discussed the strength and active  
244 elevation of the Constant score as the drivers of low total Constant, which may suggest deltoid  
245 impairment as the cause of a poor result. In addition, we were unable to obtain radiographic follow-up for  
246 most patients. We are therefore unable to comment on the presence or significance of scapular notching  
247 and radiolucencies around components. Moreover, along with other 10-year studies, we analyzed how  
248 RSA performed for various indications. Prior studies have identified different results for RSA based on  
249 indication,<sup>18</sup> and therefore grouping them together may not be the ideal way to understand results on the  
250 individual level despite higher sample sizes. Lastly, these results come from a single, high-volume  
251 shoulder arthroplasty surgeon, and therefore may not be generalizable to other practice settings. Larger,  
252 multi-surgeon or registry studies may better represent the long-term results of RSA.

253

254

## 255 **Conclusion**

256         This study presents the largest American cohort of Grammont design RSA at a minimum 10-year  
257 follow-up. While RSA provided clinically significant and durable improvements in pain and function, the  
258 complication and revision rates were higher than prior reports. Despite this, the vast majority of patients  
259 were satisfied and would have the procedure again.

260 **References**

261

262 1. Bacle G, Nové-Josserand L, Garaud P, Walch G. Long-Term Outcomes of Reverse Total Shoulder  
263 Arthroplasty: A Follow-up of a Previous Study. *J Bone Joint Surg Am.* 2017 Mar 15;99(6):454–  
264 461. doi:10.2106/JBJS.16.00223

265 2. Barco R, Savvidou OD, Sperling JW, Sanchez-Sotelo J, Cofield RH. Complications in reverse  
266 shoulder arthroplasty. *EFORT Open Rev.* 2017 Mar 13;1(3):72-80. doi:10.1302/2058-  
267 5241.1.160003.

268 3. Boileau P. Complications and revision of reverse total shoulder arthroplasty. *Orthop Traumatol*  
269 *Surg Res.* 2016 Feb;102(1 Suppl):S33-43. doi:10.1016/j.otsr.2015.06.031

270 4. Boileau P, Melis B, Duperron D, Moineau G, Rumian AP, Han Y. Revision surgery of reverse  
271 shoulder arthroplasty. *Journal of Shoulder and Elbow Surgery.* 2013 Oct 1;22(10):1359–1370.  
272 doi:10.1016/j.jse.2013.02.004

273 5. Cuff DJ, Pupello DR, Santoni BG, Clark RE, Frankle MA. Reverse Shoulder Arthroplasty for the  
274 Treatment of Rotator Cuff Deficiency: A Concise Follow-up, at a Minimum of 10 Years, of  
275 Previous Reports. *J Bone Joint Surg Am.* 2017 Nov 15;99(22):1895–1899.  
276 doi:10.2106/JBJS.17.00175

277 6. Edwards, TB, Morris, BJ. *Shoulder Arthroplasty.* 2nd ed. Philadelphia, PA: Elsevier.  
278 doi:10.1016/C2016-0-01847-8

279 7. Favard L, Levigne C, Nerot C, Gerber C, De Wilde L, Mole D. Reverse prostheses in arthropathies  
280 with cuff tear: are survivorship and function maintained over time? *Clin Orthop Relat Res.* 2011  
281 Sep;469(9):2469–2475. doi:10.1007/s11999-011-1833-y

282 8. Frankle M, Siegal S, Pupello D, Saleem A, Mighell M, Vasey M. The Reverse Shoulder Prosthesis  
283 for glenohumeral arthritis associated with severe rotator cuff deficiency. A minimum two-year  
284 follow-up study of sixty patients. *J Bone Joint Surg Am.* 2005 Aug;87(8):1697–1705.  
285 doi:10.2106/JBJS.D.02813

286 9. Gowd AK, Charles MD, Liu JN, Lalehzarian SP, Cabarcas BC, Manderle BJ, et al. Single  
287 Assessment Numeric Evaluation (SANE) is a reliable metric to measure clinically significant

- 288 improvements following shoulder arthroplasty. *J Shoulder Elbow Surg.* 2019;28:2238–2246.  
289 doi:10.1016/j.jse.2019.04.041
- 290 10. Guery J, Favard L, Sirveaux F, Oudet D, Mole D, Walch G. Reverse total shoulder arthroplasty.  
291 Survivorship analysis of eighty replacements followed for five to ten years. *J Bone Joint Surg Am.*  
292 2006 Aug;88(8):1742–1747. doi:10.2106/JBJS.E.00851
- 293 11. Kim SH, Wise BL, Zhang Y, Szabo RM. Increasing incidence of shoulder arthroplasty in the United  
294 States. *J Bone Joint Surg Am.* 2011 Dec 21;93(24):2249–2254. doi:10.2106/JBJS.J.01994
- 295 12. Melis B, Bonnevalle N, Neyton L, Lévigne C, Favard L, Walch G, et al. Glenoid loosening and  
296 failure in anatomical total shoulder arthroplasty: is revision with a reverse shoulder arthroplasty a  
297 reliable option? *J Shoulder Elbow Surg.* 2012 Mar;21(3):342–349. doi:10.1016/j.jse.2011.05.021
- 298 13. Melis B, DeFranco M, Lädermann A, Molé D, Favard L, Nérot C, et al. An evaluation of the  
299 radiological changes around the Grammont reverse geometry shoulder arthroplasty after eight to 12  
300 years. *J Bone Joint Surg Br.* 2011 Sep;93(9):1240–1246. doi:10.1302/0301-620X.93B9.25926
- 301 14. Padegimas EM, Maltenfort M, Ramsey ML, Williams GR, Parvizi J, Namdari S. Periprosthetic  
302 shoulder infection in the United States: incidence and economic burden. *J Shoulder Elbow Surg.*  
303 2015 May;24(5):741–746. doi:10.1016/j.jse.2014.11.044
- 304 15. Singh JA, Sperling JW, Schleck C, Harmsen WS, Cofield RH. Periprosthetic infections after total  
305 shoulder arthroplasty: a 33-year perspective. *J Shoulder Elbow Surg.* 2012 Nov;21(11):1534–1541.  
306 doi:10.1016/j.jse.2012.01.006
- 307 16. Sirveaux F, Favard L, Oudet D, Huquet D, Walch G, Molé D. Grammont inverted total shoulder  
308 arthroplasty in the treatment of glenohumeral osteoarthritis with massive rupture of the cuff. Results  
309 of a multicentre study of 80 shoulders. *J Bone Joint Surg Br.* 2004 Apr;86(3):388–395.  
310 doi:10.1302/0301-620x.86b3.14024
- 311 17. Tashjian RZ, Hung M, Keener JD, Bowen RC, McAllister J, Chen W, et al. Determining the  
312 minimal clinically important difference for the American Shoulder and Elbow Surgeons score,  
313 Simple Shoulder Test, and visual analog scale (VAS) measuring pain after shoulder arthroplasty. *J*  
314 *Shoulder Elbow Surg.* 2017 Jan;26(1):144–148. doi:10.1016/j.jse.2016.06.007

- 315 18. Wall B, Nové-Josserand L, O'Connor DP, Edwards TB, Walch G. Reverse total shoulder  
316 arthroplasty: a review of results according to etiology. *J Bone Joint Surg Am.* 2007 Jul;89(7):1476–  
317 1485. doi:10.2106/JBJS.F.00666
- 318 19. Zhu M, Ravi S, Frampton C, Luey C, Young S. New Zealand Joint Registry data underestimates the  
319 rate of prosthetic joint infection. *Acta Orthop.* 2016 Aug;87(4):346–350.  
320 doi:10.3109/17453674.2016.1171639

321

**322 Figure captions**

323

324 Figure 1. Patient-reported outcome measures preoperatively and at 2-5 years and final follow-up.  
325 Pain and SANE measures were significantly improved at 2-5 years and 10+ years as compared to  
326 preoperative for all three patient groups ( $P < .001$ ).

327

328 Figure 2. Timeline for complications and revisions over 10-years following reverse shoulder  
329 arthroplasty.

330

331 Figure 3. Prosthesis survival for all patients (N=471) regardless of clinical follow-up time who  
332 underwent reverse shoulder arthroplasty during the study period.

333



Table 1. Standardized phone questionnaire for patients unable to return to the clinic for 10-year follow-up.

Phone question	Possible answers
1. Have you had any shoulder surgeries since Dr. [REDACTED] performed your shoulder replacement? If yes, do you recall the date and reason for the surgery?	Yes/no  Free text
2. Using a 0-10 scale, how would you rate your pain level in your shoulder? 0 would be no pain and 10 would be the worst pain imaginable.	0-10
3. How satisfied are you with your shoulder?	Very dissatisfied, Dissatisfied, Satisfied or Very satisfied
4. How would you rate your shoulder today as a percentage of normal from 0 to 100%? 100% represents perfectly normal.	0-100%
5. Taking into account all the activities you have during your daily life, your level of pain, and also your functional impairment, do you consider your current state satisfactory?	Yes/no
6. If you had to go back and do the same surgery again, would you have the surgery?	Yes/No
7. Anything else about your shoulder you would like to share?	Free text

**Table 2.** Preoperative subject characteristics for primary and revision patients. Data is expressed as mean ( $\pm$  standard deviation or range) or number (percentage) as appropriate.

	Primary RSA N=71	Revision RSA N=23	P
Age (years)	67.4 ( $\pm$ 9.3)	63.3 ( $\pm$ 9.9)	.074
Female gender	45 (64%)	14 (61%)	.768
BMI	30.2 ( $\pm$ 7.4)	28.3 ( $\pm$ 5.0)	.261
Dominant Shoulder	46 (66%)	8 (35%)	.009
Follow-up (years)	11.4 (10-15.7)	11.6 (10-14.2)	.581

**Table 3.** Indications for primary RSA

Indication	Number (%)
Cuff tear arthropathy	54 (77%)
Proximal humerus fracture	9 (13%)
Instability or fixed dislocation	4 (6%)
Infection after rotator cuff repair	2 (3%)
Severe biconcave deformity	1 (1%)

Table 4. Comparison of studies reported in the literature with about 10 years follow-up.

	Melis et al	Bacle et al	Cuff et al	Present series
Study period	1993-2000	1995-2003	2004-2005	2004-2010
Cohort size (# of RSA)	68	87	42	93
Mean follow up (years)	9.6	12.5	11.0	11.4
Indications	CTA (48) Revision (11) Massive RCT (9)	CTA (27) Revision (21) Massive RCT (20) PTA (10) Primary OA (9)	RC deficiency (19) Failed prior RC surgery (13) Revision (10)	CTA (54) Revision (25) PHF (9) Instability or fixed dislocation (4) Post infection (2) Biconcave deformity (1)
Implant Design	Grammont	Grammont	Lateralized COR	Grammont
Survivorship at 10 years	-	93%	-	80.5%
Complication rate	14%	29%	-	64%
Revision rate	19%	12%	9%	43%
Functional outcome scores (mean)	CS (A): 60	CS (A): 55 CS (R): 86	ASES: 74 SST: 7 No ASES deterioration from mid to long term follow up.	SANE: 73 Pain: 2.0
Satisfaction	84% VS or S	-	-	82% VS or S
Mean active elevation (degrees)	132	131	126 Slight deterioration from mid to long term follow up.	-





